15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report

Zuily, Stéphane; Barbhaiya, Medha; Costenbader, Karen H.; Erkan, Doruk

doi:10.1007/978-3-319-55442-6_15

Cited by 6 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 During the 15th International Congress on aPL (2016) the management of thrombocytopenia, cardiac valve disease, nephropathy, and livedoid vasculopathyrelated skin ulcers was discussed extensively, as part of the disease spectrum beyond thrombosis and pregnancy morbidity. 4 Given above, the objectives of the 16th International Congress on aPL Task Force on Clinical Manifestations of APS were to update and critically analyze: a) the "APS" definition; b) the current knowledge on non-traditional manifestations associated with aPL; and c) risk stratification strategies in aPL-positive patients.…”

Section: Introductionmentioning

confidence: 99%

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Sciascia

Radin

Cecchi

et al. 2021

Lupus

Self Cite

View full text Add to dashboard Cite

The objectives of the 16th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Clinical Manifestations of Antiphospholipid Syndrome (APS) were to critically analyze: a) the definition of “APS”; b) the current knowledge on non-traditional manifestations associated with aPL; and c) the risk stratification strategies in aPL-positive patients. The quality of evidence was assessed by the GRADE system. The task force concluded that: a) APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles; b) current literature supports the role for aPL testing in cases of thrombocytopenia and recurrent cardiac events but are limited by vast heterogeneity, providing an overall low-to-very low level of evidence; and c) risk stratification strategies in aPL-positive patients, such as aPL-Score and Global APS Score, can be useful in clinical practice. International multicenter studies are still highly needed to improve the quality of available evidence and consequently the strength of future recommendations.

show abstract

Section: Introductionmentioning

confidence: 99%

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Sciascia

Radin

Cecchi

et al. 2021

Lupus

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dermatologic lesions during SAPL are common, although nonspecific, sometimes inaugural, and may be the only clinical manifestation [1,2]. However, extensive superficial skin necrosis remains extremely rare, reported in only 2% of cases [2,3].…”

Section: Discussionmentioning

confidence: 99%

Special presentation of antiphospholipid syndrome

Couissi,

Soughi,

El Fid

et al. 2023

Our Dermatol Online

View full text Add to dashboard Cite

Antiphospholipid antibody syndrome (APAS) is a condition of acquired thrombophilia due to autoantibodies directed against membrane phospholipids and/or their cofactors. It may be primary or part of a systemic autoimmune disease, such as systemic lupus erythematosus (SLE). Dermatological lesions during APS are frequent, although non-specific, sometimes inaugural, and may be the only clinical manifestation. However, extensive cutaneous necrosis is rare and treatment is based on anticoagulants and appropriate local care. Herein, we report a case of multiple extensive cutaneous necroses in a female with SLE. The particularity of our case is the presence of two types of lesions, necrotizing plaques surmounted by hemorrhagic bullae surrounded by a purpuric border specific to antiphospholipid syndrome and ecchymotic plaques evolving according to the color of the biligenesis, which may be consistent with coagulopathy, in particular, a protein C or S deficiency, hence the interest in good knowledge and semiological analysis. Key words: Anti-phospholipid antibody syndrome; Extensive skin necrosis; Systemic lupus erythematosus

show abstract

“…[4][5][6] Currently, the Task Force on APS Classification is working on the development of new diagnostic criteria. 6 APS can be primary, or secondary, associated with other disorders, of which systemic lupus erythematosus (SLE) is the most important one in children. 4 Prevention of (secondary) thrombosis and immunomodulation are the cornerstones of APS treatment.…”

Section: Introductionmentioning

confidence: 99%

“…In the pediatric population, this definition is of limited use, as in children nonthrombotic clinical manifestations such as thrombocytopenia, hemolytic anemia and neurological disorders, including chorea, can precede thrombosis. [4][5][6] Currently, the Task Force on APS Classification is working on the development of new diagnostic criteria. 6 APS can be primary, or secondary, associated with other disorders, of which systemic lupus erythematosus (SLE) is the most important one in children.…”

Section: Introductionmentioning

confidence: 99%

Successful Rituximab Therapy for Pediatric Antiphospholipid-Related Chorea: A Case Report and Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Chorea is considered a non-thrombotic manifestation of the antiphospholipid syndrome, often preceding thrombotic events in children. It can be present in up to 5% of pediatric patients with antiphospholipid syndrome. Immunomodulatory treatment regimens seem to be successful in these patients, emphasizing the underlying immunological etiology. Corticosteroids are considered first line treatment, but chorea tends to be therapy-resistant and guidelines about second-line therapy in children are solely based on small case studies. We present a case of a therapy-resistant chorea, successfully treated with rituximab. Furthermore, we give an overview of the existing literature concerning rituximab for the treatment of chorea in children. Our findings indicate that rituximab can be considered a safe option to treat APS-related chorea in children.

show abstract

15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report

Cited by 6 publications

References 36 publications

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Special presentation of antiphospholipid syndrome

Successful Rituximab Therapy for Pediatric Antiphospholipid-Related Chorea: A Case Report and Review of the Literature

Contact Info

Product

Resources

About